1848636|t|Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.
1848636|a|The metabolism of the cardioselective beta-blocker metoprolol is under genetic control of the debrisoquine/sparteine type. The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs. We investigated if the latter also applies to the beta-2 adrenoceptor antagonism by metoprolol. The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia. By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy. Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o. Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2. Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol. In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%). Higher metoprolol/alpha-hydroxymetoprolol ratios in PMs were predictive for higher R-/S-isomer ratios of unchanged drug. There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)
1848636	0	12	Debrisoquine	ChemicalEntity	D003647
1848636	52	67	beta-2 receptor	GeneOrGeneProduct	154
1848636	88	98	metoprolol	ChemicalEntity	D008790
1848636	171	181	metoprolol	ChemicalEntity	D008790
1848636	214	226	debrisoquine	ChemicalEntity	D003647
1848636	227	236	sparteine	ChemicalEntity	D013034
1848636	390	409	beta-1 adrenoceptor	GeneOrGeneProduct	153
1848636	442	452	metoprolol	ChemicalEntity	D008790
1848636	511	530	beta-2 adrenoceptor	GeneOrGeneProduct	154
1848636	545	555	metoprolol	ChemicalEntity	D008790
1848636	603	613	metoprolol	ChemicalEntity	D008790
1848636	617	628	terbutaline	ChemicalEntity	D013726
1848636	637	648	hypokalemia	DiseaseOrPhenotypicFeature	D007008
1848636	732	742	metoprolol	ChemicalEntity	D008790
1848636	838	848	metoprolol	ChemicalEntity	D008790
1848636	944	955	terbutaline	ChemicalEntity	D013726
1848636	1059	1069	metoprolol	ChemicalEntity	D008790
1848636	1149	1160	terbutaline	ChemicalEntity	D013726
1848636	1227	1236	potassium	ChemicalEntity	D011188
1848636	1238	1249	terbutaline	ChemicalEntity	D013726
1848636	1251	1261	metoprolol	ChemicalEntity	D008790
1848636	1294	1317	alpha-hydroxymetoprolol	ChemicalEntity	C029504
1848636	1389	1399	metoprolol	ChemicalEntity	D008790
1848636	1409	1419	metoprolol	ChemicalEntity	D008790
1848636	1434	1445	terbutaline	ChemicalEntity	D013726
1848636	1512	1522	metoprolol	ChemicalEntity	D008790
1848636	1523	1546	alpha-hydroxymetoprolol	ChemicalEntity	C029504
1848636	1652	1662	metoprolol	ChemicalEntity	D008790
1848636	1691	1701	metoprolol	ChemicalEntity	D008790
1848636	Negative_Correlation	153	D008790	No
1848636	Positive_Correlation	D013726	D007008	No
1848636	Association	D008790	D013034	No
1848636	Association	D008790	D003647	No
1848636	Positive_Correlation	D008790	D013726	Novel
1848636	Negative_Correlation	D008790	D007008	No
1848636	Negative_Correlation	D008790	154	Novel